SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today reported that it has received the $5 million milestone payment previously announced on July 20, 2007 relating to progress on clinical product development strategy under its over-the-counter (OTC) license agreement with Schering-Plough HealthCare Products, Inc. for proton pump inhibitor (PPI) products using Santarus’ patented PPI technology.
